Pulmonary hypertension is ameliorated in mice deficient in thrombin‐activatable fibrinolysis inhibitor
Open Access
- 23 March 2010
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 8 (4) , 808-816
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- New insights into the molecular mechanisms of the fibrinolytic systemJournal of Thrombosis and Haemostasis, 2009
- Endothelial injury in the initiation and progression of vascular disordersVascular Pharmacology, 2007
- Protective role of protein C inhibitor in monocrotaline‐induced pulmonary hypertensionJournal of Thrombosis and Haemostasis, 2006
- Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- Endothelial Dysfunction in Pulmonary HypertensionCirculation, 2004
- Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in ratsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2002
- Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine lifeJournal of Clinical Investigation, 2002
- Intratracheal Administration of Activated Protein C Inhibits Bleomycin-induced Lung Fibrosis in the MouseAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Plasma coagulation profiles in patients with severe primary pulmonary hypertensionEuropean Respiratory Journal, 1998
- Coagulation and Fibrinolytic Profiles in Patients With Severe Pulmonary HypertensionChest, 1996